Cautious Outlook on BioNTech SE: Strong Q3 Performance Overshadowed by Uncertain Future in Vaccine Sales and Oncology Pipeline
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...
FiercePharma15h
BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
BioSpace15h
BioNTech Handily Beats Q3 Expectations, Trims Full-Year Revenue Guidance
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
BioNTech Beats Expectations, Gives Update on Cancer Drugs
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per diluted ...
Business Insider1d
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 billion, largely driven by the successful launch of its variant-adapted ...
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.
Rand Paul hits 'Biden/Harris CDC' over COVID-19 vaccine guidance for 6-month-olds
Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...
Fact Check: Q&A on the 2024-2025 COVID-19 Vaccines
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
Seeking Alpha17d
BioNTech and Moderna: A tale of two mRNA developers
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...
Morningstar4d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.
Seeking Alpha17d
BioNTech, OncoC4 Phase 3 study put on partial hold by FDA
BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug candidate BNT316/ONC-392 in the treatment of non-small cell lung cancer ...